Size means little in light of this company's prospects.

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Recent developments in health sector include no longer needing to stop GLP-1 drugs before surgery, FDA warning against a ...

A newly published study in the New England Journal of Medicine highlighted this week that Novo Nordisk’s (NVO) GLP-1 agonist ...

The company is expected to offer data on the higher dosing arms of 60, 80 and 100 milligrams at Obesity Week, which is organized by the Obesity Society and takes place Nov. 3-6 in San Antonio, Texas.

The world’s latest AI machine is powered by the success of two products: Nvidia’s chips and Novo Nordisk’s weight-loss drugs.

A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis ...

The U.S. Food and Drug Administration on Friday warned patients and health care professionals not to use compounded drugs, ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced promising results from the first part of its ESSENCE trial, showing that ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...